medication during pregnancy - MGH Center for Women's Mental Health

Dr. Lee Cohen in Ob-Gyn News: Using SSRIs in Pregnancy

Over the last decade, attention in the medical literature has gathered logarithmically to focus on potentially efficacious treatments for perinatal depression. Studies of relevant databases, editorials, and various reviews have addressed the reproductive safety concerns of antidepressant treatments, particularly selective serotonin reuptake inhibitors (SSRIs) on one hand, and the impact of untreated maternal psychiatric illness on fetal and maternal well-being on the other.

By MGH Center for Women's Mental Health|2024-03-31T10:40:13-04:00December 13th, 2012|Antidepressants, ObGyn News, Outcomes, Pregnancy & Medications|Comments Off

SSRIs and Pregnancy: Putting the Risks and Benefits into Perspective

Prozac hit the market in 1988, the first selective serotonin reuptake inhibitor (SSRI) antidepressant approved by the FDA for the treatment of depression. Because it was safer and more tolerable than the antidepressants that preceded it, Prozac was soon the most commonly prescribed antidepressant in the United States.

By MGH Center for Women's Mental Health|2015-08-06T13:57:24-04:00December 6th, 2012|Antidepressants, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off

Use of Antipsychotic Medications in Pregnancy Increases Risk of Gestational Diabetes

Atypical antipsychotic medications are commonly used for the treatment of schizophrenia and bipolar disorder. Despite the increasing use of these medications in women of child-bearing age, there is still relatively little data regarding the reproductive safety of these medications.

By Ruta Nonacs, MD PhD|2024-04-14T16:18:01-04:00July 17th, 2012|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Pregnancy Outcomes|Comments Off

Topiramate (Topamax) Associated with an Increased Risk of Oral Clefts

Topiramate (marketed as a Topamax), in addition to its use for the treatment of epilepsy, is now being prescribed to reproductive aged women for a broad spectrum of indications, including migraine headaches, weight control, and mood stabilization. Limited information is available on its reproductive safety; however, the preliminary data we do have raises some concerns regarding the use of topiramate in pregnancy.

By MGH Center for Women's Mental Health|2015-08-12T16:57:19-04:00February 8th, 2012|Anti-Epileptic Drugs, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off

SSRIs and PPHN: The FDA Revises Its Warning

In 2006, Chambers and colleagues published an article in the New England Journal of Medicine linking SSRI use during late pregnancy to an increased risk of persistent pulmonary hypertension in the newborn (PPHN). Based on these findings, the “Usage in Pregnancy” section on the labels for SRRI antidepressants was updated to include the following warning: “Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN).”

By MGH Center for Women's Mental Health|2015-08-12T17:01:20-04:00January 17th, 2012|Antidepressants, Child Outcomes, Neonatal Symptoms, Outcomes, Pregnancy & Medications|Comments Off

In Utero Exposure to Antipsychotics

May 2011, ObGyn News, Lee S. Cohen, MD

By MGH Center for Women's Mental Health|2020-11-26T08:40:43-04:00May 17th, 2011|Antipsychotic Medications, Outcomes, Pregnancy & Medications|Comments Off

New FDA Warning on the Use of Antipsychotic Medications in Pregnancy

On February 22, 2011, the U.S. Food and Drug Administration (FDA) informed healthcare professionals that drug labels for the entire class of antipsychotic drugs have been updated to include warnings regarding the use of antipsychotic drugs during pregnancy. The new drug labels now contain more details on the potential risk for abnormal muscle movements (extrapyramidal signs or EPS) and withdrawal symptoms in newborns exposed to these drugs during the third trimester of pregnancy.

By MGH Center for Women's Mental Health|2015-07-28T14:26:32-04:00March 9th, 2011|Antipsychotic Medications, Child Outcomes, Pregnancy & Medications|Comments Off

Should SSRIs Be Tapered Prior To Delivery?

Increased muscle tone, jitteriness, sleep disturbance, irritability, feeding problems, mild respiratory distress and myoclonus have been reported as symptoms of a potential neonatal distress syndrome related to exposure to SSRIs in late pregnancy. The average duration of symptoms reported is 48 hours. It is estimated that between 25-30% of SSRI-exposed infants are at risk for this syndrome. No treatment intervention is required. Reassuringly, follow-up studies have shown that at 2, 4, 6, and 8 months SSRI-exposed infants are indistinguishable from control infants without known exposure.

By MGH Center for Women's Mental Health|2015-08-12T17:01:53-04:00September 8th, 2010|Anxiety Disorders, Depressive Disorders, Medication, Pregnancy & Medications, Psychiatric Disorders During Pregnancy, Treatment|Comments Off

Antidepressants and Risk of Spontaneous Abortion

Although the last several decades of research have yielded important findings regarding the safety of antidepressants during pregnancy, some areas are still understudied. For example, there are no conclusive results concerning the risk of spontaneous abortions following antidepressant exposure during the first trimester. Several recent meta-analyses, including one from the Motherisk program (Hemels, 2005), have observed an increased risk of spontaneous abortion among women taking antidepressants.

By MGH Center for Women's Mental Health|2015-08-12T16:45:03-04:00June 21st, 2010|Antidepressants, Outcomes, Pregnancy & Medications, Pregnancy Outcomes|Comments Off

Valproic Acid and the Risk of Major Malformations

Previous studies have indicated that infants exposed to valproic acid in pregnancy are at increased risk for a range of malformations, including neural tube defects. While these studies have shown an association between valproic acid and various malformations, they have been limited in their ability to quantify the risk of certain, less common malformations. To do this, large population-based case–control studies are more appropriate.

By MGH Center for Women's Mental Health|2015-08-12T16:43:09-04:00June 14th, 2010|Anti-Epileptic Drugs, Mood Stabilizers, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off